Dispatch Biotherapeutics Inc. is taking aim at solid tumors with a new viral vector/antigen technology backed by major industry names such as Arch Venture Partners and Bristol Myers Squibb Co. With offices in Philadelphia and San Francisco, Dispatch has raised $216 million since its founding in 2022. The firm’s platform delivers a cell-specific viral vector carrying a novel, universal antigen called Flare that tags solid, epithelial-derived tumor cells. Acting as a beacon, the Flare antigen directs the immune system to find and clear the cancer cells without harming healthy tissue. Read More
Researchers from Peking University and the China-Japan Friendship Hospital have gained new insights into the role of triggering receptor expressed on myeloid cells-1 (TREM-1) in traumatic brain injury (TBI). Cerebral damage resulting from external mechanical impacts causes TBI, which is a leading cause of morbidity and mortality worldwide. Read More
Opus Genetics Inc. has entered a strategic partnership with the Global RDH12 Alliance to advance Opus’ gene therapy program for patients with vision loss due to retinol dehydrogenase 12 (RDH12) gene mutations. Read More
Akari Therapeutics plc announced that it is continuing key research on its antibody-drug conjugate (ADC) payload PH1 to further demonstrate its ability to target cancers fueled by oncogenic drivers. PH1 is a spliceosome modulator designed to disrupt RNA splicing within cells. It binds spliceosome proteins SF3B1 and PH5α and targets normal splicing of pre-mRNA. PH1 is a spliceosome modulator designed to disrupt RNA splicing within cells. It binds spliceosome proteins SF3B1 and PH5α and targets normal splicing of pre-mRNA. Read More
Albireo Ltd. has patented new benzothia(di)azepine compounds acting as ileal sodium/bile acid cotransporter (SLC10A2; IBAT; ASBT) and/or sodium-bile acid cotransporter (SLC10A1; NTCP) inhibitors reported to be useful for the treatment of diabetes, cardiovascular, gastrointestinal, liver and renal disorders. Read More
The combination of interleukin-2 (IL-2) agonism with programmed cell death protein 1 (PD-1) checkpoint inhibition has previously demonstrated synergistic efficacy in promoting antitumor T-cell responses. However, the incompatible dose levels and dosing schedules of the two therapeutic mechanisms have made their integration within a single molecule challenging. Read More
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have synthesized new mast/stem cell growth factor receptor kit (KIT; c-KIT; CD117) inhibitors reported to be useful for the treatment of urticaria. Read More
Crossbow Therapeutics Inc. has nominated its second development candidate, CBX-663, a T-cell engager for the treatment of a broad range of solid tumors and hematologic malignancies. Read More
Jacobio Pharmaceuticals Co. Ltd. has reported new fused tetracyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer. Read More
Work at Erciyes University has led to the discovery of antimicrobial peptides with potential for the treatment of bacterial and fungal infections. Read More
A hallmark of liver fibrosis is the differentiation of hepatic stellate cells (HSCs) into myofibroblast-like cells, which are responsible for excessive extracellular matrix deposition. Among the key mediators of HSC activation, transforming growth factor-beta 1 (TGF-β1) is considered the most potent pro-fibrotic cytokine. Read More
